(Q45149092)

10 December 2017

title

Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia (English)

1 reference

10 December 2017

2

A Colao

1 reference

10 December 2017

B Merola

1

1 reference

10 December 2017

E Caruso

3

1 reference

10 December 2017

F Sarnacchiaro

4

1 reference

10 December 2017

I Lancranjan

5

1 reference

10 December 2017

G Lombardi

6

1 reference

10 December 2017

G Schettini

7

1 reference

10 December 2017

publication date

1 March 1992

1 reference

Journal of Endocrinological Investigation

10 December 2017

published in

1 reference

10 December 2017

volume

15

1 reference

10 December 2017

issue

3

1 reference

10 December 2017

page(s)

173-176

1 reference

Long-term Treatment of Galactorrhoea and Hypogonadism with Bromocriptine

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03348700

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348700

Effects of bromocriptine on pituitary tumour size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348700

Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348700

Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03348700

Rapid regression of pituitary prolactinomas during bromocriptine treatment

21 January 2018

1 reference

12 December 2020

Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function

1 reference

12 December 2020

Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR)

1 reference

12 December 2020

Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas

1 reference

12 December 2020

Regression of pituitary prolactinoma after treatment with bromocriptine

1 reference

12 December 2020

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03348700

1 reference

Dimensions Publication ID

10 December 2017

1005874514

0 references

1 reference